← boardnext 2027-03-12next 2027-08
TVTX
Travere Therapeutics, Inc.distress 2/10 · well-funded / low risk$55.33-2%today-6% from 52w high
Lead: Homocystinuria · target CBS
Revenue
$127M
Liquidity
$78M
Runway
—
Shares 1y
+4%
Price & events
+86.1% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.7%
1D
+0.1%
1W
-1.1%
1M
+35.5%
3M
+87.9%
6M
+243.0%
1Y
+465.7%
2Y
+318.2%
5Y
+104.9%
All
Overview
- Market Cap
- $5.14B
- Volume
- 109.69K
- 52 Week Range
- $15.32 – $59.03
- Total Shares
- 92.99M
- Float Shares
- 86.99M
- Short %
- 17.84%
- % Held by Insiders
- 0.80%
- % Held by Institutions
- 113.76%
- RVOL
- 0.06x
- Beta
- 1.11
Pipeline stages · 2 programs
Sparsentan
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pegtibatinase
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 4 trials · 3 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-03-12 Estimated 50% readout ~2027-04-26 | Phase 2 | Sparsentan | Focal Segmental Glomerulosclerosis, Minimal Change Disease, Immunoglobulin A Nephropathy, IgA Vasculitis, Alport Syndrome | — | recruiting |
| 2027-08 Estimated 50% readout ~2027-10-15 | Phase 3 | Pegtibatinase | Homocystinuria | — | recruiting |
| 2030-08 Estimated 50% readout ~2030-10-15 | Phase 3 | Pegtibatinase | Homocystinuria | — | enrolling by invitation |
| 2026-06 | Phase 1/2 | Pegtibatinase | Homocystinuria | 32 | active not recruiting |
Catalyst news & presentations · 10
- 2026-08-06earningsEarningsEarnings releaseyahoo
- April 13, 2026PDUFAPDUFAFILSPARI (sparsentan) · New PDUFA target action date after extension due to Major Amendment.SEC 8-K
- 2026-01-13pdufa extensionFILSPARI (sparsentan) · FDA extended review timeline after determining responses constituted a Major Amendment.SEC 8-K
- January 13, 2026PDUFAPDUFAFILSPARI · PDUFA target action date for sNDA traditional approvalSEC 8-K
- 2025-09-10fda agreementFILSPARI · FDA informs no advisory committee needed for sNDASEC 8-K
- second quarter of 2025filing acceptanceFiled (NDA/BLA)sparsentan · Company expects FDA notice regarding acceptance and review timelineSEC 8-K
- 2025-04-29partnershipFILSPARI (sparsentan) · Company expects $17.5 million milestone payment from CSL Vifor following EU standard MA.SEC 8-K
- around the end of the first quarter of 2025regulatory submissionFiled (NDA/BLA)FILSPARI · Planned sNDA submission for traditional approval based on Phase 3 DUPLEX and Phase 2 DUET studiesSEC 8-K
- March 17, 2025regulatory submissionFiled (NDA/BLA)sparsentan · sNDA submitted to FDA seeking priority review for traditional approvalSEC 8-K
- 2024-09-26enrollment delaypegtibatinase · Voluntary pause of enrollment in Phase 3 HARMONY Study for classical homocystinuria due to manufacturing scale-up issues; earliest restart in 2026SEC 8-K
Approved drugs (1)
- FILSPARISPARSENTAN2023 · Prescription
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $58 (+5% upside) · 14 analysts
- 2026-06-25GuggenheimBuy
- 2026-06-22WedbushOutperform
- 2026-06-18Evercore ISI GroupOutperform
- 2026-06-15CitigroupBuy
- 2026-06-12Wells FargoOverweight
- 2026-06-03CitigroupBuy
Competitors — CBS
- none identified
Recent news
- 2026-07-22Travere Therapeutics, Inc. Stock 12‑Month Price Target Raised to $58.71, Implies 4% Upside - TradingView
- 2026-07-21ETFs Investing in Travere Therapeutics, Inc. Stocks - TradingView
- 2026-07-17Law firm probes Travere Therapeutics officers f... - Pluang
- 2026-07-10Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 2026-07-09Sandra Calvin to Retire as Travere Therapeutics CAO; John Torell Named Successor - TradingView
- 2026-07-09Travere Therapeutics (NASDAQ: TVTX) plans CAO transition as Sandra Calvin retires - Stock Titan
- 2026-07-08Everest Medicines Announces Close of Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib - Macau Business
- 2026-07-07Will Travere’s Removal From Key Russell Value Indices Change Travere Therapeutics' (TVTX) Narrative? - simplywall.st
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.